Intellectual Property Bulletin - Winter 2021 | Fenwick & West LLP
— Hayan Yoon In two 2019 rulings , the Federal Circuit invoked the “written description requirement” of 35 U.S.C. § 112 to require evidentiary support for therapeutic efficacy. Now that the Supreme Court has declined to hear one of those cases, “written description” will continue to present a hurdle to patentability, in addition to the utility and enablement requirements. Litigation-Proofing Your Trade Secrets: Practical Steps to Ensure They’re Enforceable in Court — Robert Counihan and Jedediah Wakefield Trade secret litigation is on the rise, and new case law related to enfor...